Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model

Pinku Mukherjee, Teresa L. Tinder, Latha B. Pathangey, Lieping Chen, Sandra J Gendler

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

To study immunology in breast tumors, we have utilized a mammary gland adenocarcinoma model in which mice develop spontaneous tumors of the mammary gland which are initiated at puberty and express a human tumor antigen, MUC1. MUC1 (CD227) is over-expressed in 90% of human breast cancers and its glycosylation status and pattern of expression in cancer cells is altered. Humoral and cellular responses to MUC1 have been reported in breast cancer patients and therefore, MUC1 is being evaluated as a target for immune intervention. This mouse model of spontaneous breast cancer allows the evaluation of anti-MUC1 immune responses at all stages of the disease. In this report, we review the model as it pertains to a) the development of the tumor, b) MUC1 expression, and the native immune responses against MUC1 as tumors progress, and c) the immune suppressive microenvironment within the developing tumor. Finally, we report our latest findings describing the therapeutic efficacy of adoptively transferred MUC1-specific cytotoxic T lymphocytes (MUC1-CTL) in these mice and discuss ways to increase their effectiveness by agonistic monoclonal antibody against CD137 T cell costimulatory molecule.

Original languageEnglish (US)
Pages (from-to)53-63
Number of pages11
JournalBreast Disease
Volume20
StatePublished - 2004

Fingerprint

Cytotoxic T-Lymphocytes
Breast Neoplasms
Human Mammary Glands
Neoplasms
Therapeutics
Neoplasm Antigens
Puberty
Allergy and Immunology
Glycosylation
Adenocarcinoma
Monoclonal Antibodies
T-Lymphocytes

ASJC Scopus subject areas

  • Surgery

Cite this

Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. / Mukherjee, Pinku; Tinder, Teresa L.; Pathangey, Latha B.; Chen, Lieping; Gendler, Sandra J.

In: Breast Disease, Vol. 20, 2004, p. 53-63.

Research output: Contribution to journalArticle

Mukherjee, Pinku ; Tinder, Teresa L. ; Pathangey, Latha B. ; Chen, Lieping ; Gendler, Sandra J. / Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. In: Breast Disease. 2004 ; Vol. 20. pp. 53-63.
@article{9df5fdcf46194096a31d899c14fcd151,
title = "Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model",
abstract = "To study immunology in breast tumors, we have utilized a mammary gland adenocarcinoma model in which mice develop spontaneous tumors of the mammary gland which are initiated at puberty and express a human tumor antigen, MUC1. MUC1 (CD227) is over-expressed in 90{\%} of human breast cancers and its glycosylation status and pattern of expression in cancer cells is altered. Humoral and cellular responses to MUC1 have been reported in breast cancer patients and therefore, MUC1 is being evaluated as a target for immune intervention. This mouse model of spontaneous breast cancer allows the evaluation of anti-MUC1 immune responses at all stages of the disease. In this report, we review the model as it pertains to a) the development of the tumor, b) MUC1 expression, and the native immune responses against MUC1 as tumors progress, and c) the immune suppressive microenvironment within the developing tumor. Finally, we report our latest findings describing the therapeutic efficacy of adoptively transferred MUC1-specific cytotoxic T lymphocytes (MUC1-CTL) in these mice and discuss ways to increase their effectiveness by agonistic monoclonal antibody against CD137 T cell costimulatory molecule.",
author = "Pinku Mukherjee and Tinder, {Teresa L.} and Pathangey, {Latha B.} and Lieping Chen and Gendler, {Sandra J}",
year = "2004",
language = "English (US)",
volume = "20",
pages = "53--63",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",

}

TY - JOUR

T1 - Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model

AU - Mukherjee, Pinku

AU - Tinder, Teresa L.

AU - Pathangey, Latha B.

AU - Chen, Lieping

AU - Gendler, Sandra J

PY - 2004

Y1 - 2004

N2 - To study immunology in breast tumors, we have utilized a mammary gland adenocarcinoma model in which mice develop spontaneous tumors of the mammary gland which are initiated at puberty and express a human tumor antigen, MUC1. MUC1 (CD227) is over-expressed in 90% of human breast cancers and its glycosylation status and pattern of expression in cancer cells is altered. Humoral and cellular responses to MUC1 have been reported in breast cancer patients and therefore, MUC1 is being evaluated as a target for immune intervention. This mouse model of spontaneous breast cancer allows the evaluation of anti-MUC1 immune responses at all stages of the disease. In this report, we review the model as it pertains to a) the development of the tumor, b) MUC1 expression, and the native immune responses against MUC1 as tumors progress, and c) the immune suppressive microenvironment within the developing tumor. Finally, we report our latest findings describing the therapeutic efficacy of adoptively transferred MUC1-specific cytotoxic T lymphocytes (MUC1-CTL) in these mice and discuss ways to increase their effectiveness by agonistic monoclonal antibody against CD137 T cell costimulatory molecule.

AB - To study immunology in breast tumors, we have utilized a mammary gland adenocarcinoma model in which mice develop spontaneous tumors of the mammary gland which are initiated at puberty and express a human tumor antigen, MUC1. MUC1 (CD227) is over-expressed in 90% of human breast cancers and its glycosylation status and pattern of expression in cancer cells is altered. Humoral and cellular responses to MUC1 have been reported in breast cancer patients and therefore, MUC1 is being evaluated as a target for immune intervention. This mouse model of spontaneous breast cancer allows the evaluation of anti-MUC1 immune responses at all stages of the disease. In this report, we review the model as it pertains to a) the development of the tumor, b) MUC1 expression, and the native immune responses against MUC1 as tumors progress, and c) the immune suppressive microenvironment within the developing tumor. Finally, we report our latest findings describing the therapeutic efficacy of adoptively transferred MUC1-specific cytotoxic T lymphocytes (MUC1-CTL) in these mice and discuss ways to increase their effectiveness by agonistic monoclonal antibody against CD137 T cell costimulatory molecule.

UR - http://www.scopus.com/inward/record.url?scp=9344237270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9344237270&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 53

EP - 63

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

ER -